Midostaurin

Acute Myeloid Leukemia

Richard Stone, MDSmall moleculePhase 3Active

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 63/ 100
Competitive Position: 59/ 100

Competitive context

587 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
Amsacrine University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-Vincristine Janssen Research & Development, LLC	Phase 3	BBB
Aclacinomycin Chinese PLA General Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Midostaurin is also rated in:

acute myeloid leukemia by FAB classificationActive

B

Indicative · Phase 2

63 / 100

myelodysplastic syndrome with excess blasts-2Active

B

Indicative · Phase 3

62 / 100

myelodysplastic syndromeActive

B

Indicative · Phase 2/3

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.